Literature DB >> 21453899

Mu opioid receptors in pain management.

Gavril Pasternak1, Ying-Xian Pan.   

Abstract

Most of the potent analgesics currently in use act through the mu opioid receptor. Although they are classified as mu opioids, clinical experience suggests differences among them. The relative potencies of the agents can vary from patient to patient, as well as the side-effect profiles. These observations, coupled with pharmacological approaches in preclinical models, led to the suggestion of multiple subtypes of mu receptors. The explosion in molecular biology has led to the identification of a single gene encoding mu opioid receptors. It now appears that this gene undergoes extensive splicing, in which a single gene can generate multiple proteins. Evidence now suggests that these splice variants may help explain the clinical variability in responses among patients.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21453899      PMCID: PMC4014005          DOI: 10.1016/j.aat.2010.12.008

Source DB:  PubMed          Journal:  Acta Anaesthesiol Taiwan


  63 in total

1.  Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F.

Authors:  Y X Pan; J Xu; E Bolan; A Chang; L Mahurter; G Rossi; G W Pasternak
Journal:  FEBS Lett       Date:  2000-01-28       Impact factor: 4.124

2.  Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene.

Authors:  Y X Pan; J Xu; L Mahurter; E Bolan; M Xu; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 3.  Strategies to manage the adverse effects of oral morphine: an evidence-based report.

Authors:  N Cherny; C Ripamonti; J Pereira; C Davis; M Fallon; H McQuay; S Mercadante; G Pasternak; V Ventafridda
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

4.  A pituitary endorphin with novel properties.

Authors:  L I Lowney; S B Gentleman; A Goldstein
Journal:  Life Sci       Date:  1979-06-18       Impact factor: 5.037

5.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

6.  Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors.

Authors:  G W Pasternak; S R Childers; S H Snyder
Journal:  Science       Date:  1980-05-02       Impact factor: 47.728

7.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  Classification of multiple morphine and enkephalin binding sites in the central nervous system.

Authors:  B L Wolozin; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

10.  Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro.

Authors:  G W Pasternak; S R Childers; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1980-09       Impact factor: 4.030

View more
  9 in total

1.  Modulatory effects of photobiomodulation in the anterior cingulate cortex of diabetic rats.

Authors:  Igor Rafael Correia Rocha; Marucia Chacur
Journal:  Photochem Photobiol Sci       Date:  2021-05-30       Impact factor: 3.982

Review 2.  Designing Safer Analgesics via μ-Opioid Receptor Pathways.

Authors:  H C Stephen Chan; Dillon McCarthy; Jianing Li; Krzysztof Palczewski; Shuguang Yuan
Journal:  Trends Pharmacol Sci       Date:  2017-09-19       Impact factor: 14.819

Review 3.  Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids.

Authors:  Suhani Dalal; Ahish Chitneni; Amnon A Berger; Vwaire Orhurhu; Bilal Dar; Bennett Kramer; Anvinh Nguyen; John Pruit; Charles Halsted; Alan D Kaye; Jamal Hasoon
Journal:  Health Psychol Res       Date:  2021-08-06

4.  Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect.

Authors:  Nunzio Vicario; Rosalba Parenti; Giuseppina Arico'; Rita Turnaturi; Giovanna Maria Scoto; Santina Chiechio; Carmela Parenti
Journal:  Mol Pain       Date:  2016-09-02       Impact factor: 3.395

5.  Heterodimerization of Mu Opioid Receptor Protomer with Dopamine D2 Receptor Modulates Agonist-Induced Internalization of Mu Opioid Receptor.

Authors:  Lakshmi Vasudevan; Dasiel O Borroto-Escuela; Jelle Huysentruyt; Kjell Fuxe; Deepak K Saini; Christophe Stove
Journal:  Biomolecules       Date:  2019-08-14

6.  Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based κ-Opioid Receptor (KOR) Agonists Designed for PET Studies.

Authors:  Giovanni Tangherlini; Frederik Börgel; Dirk Schepmann; Samuel Slocum; Tao Che; Stefan Wagner; Katrin Schwegmann; Sven Hermann; Nadine Mykicki; Karin Loser; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2020-09-01       Impact factor: 3.466

Review 7.  Opioids and Vitamin C: Known Interactions and Potential for Redox-Signaling Crosstalk.

Authors:  Mackenzie Newman; Heather Connery; Jonathan Boyd
Journal:  Antioxidants (Basel)       Date:  2022-06-27

Review 8.  Which idea is better with regard to immune response? Opioid anesthesia or opioid free anesthesia.

Authors:  Barbara Lisowska; Jakub Jakubiak; Katarzyna Siewruk; Maria Sady; Dariusz Kosson
Journal:  J Inflamm Res       Date:  2020-11-05

9.  In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.

Authors:  Marthe M Vandeputte; Annelies Cannaert; Christophe P Stove
Journal:  Arch Toxicol       Date:  2020-07-31       Impact factor: 5.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.